Avid Bioservices Inc (CDMO)

[cjgaddy]

Rolf Brekken (PPHM/SAB) speaking 1-9-16 at Special AACR Tumor Microenvironment Conf. in San Diego. Note that the chair of Session5 that our Dr. Brekken is speaking in is Dr. Joan Massague, who is the DIRECTOR of Memorial Sloan Kettering Institute.

Jan7-10 2016: “AACR's The Function of Tumor Microenvironment in Cancer Progression Conf.”, SanDiego
“This AACR Special Conference will focus on discussing the emerging concepts in stromal cell and ECM heterogeneity, stromal cell metabolism, early events in carcinogenesis involving contributions from tumor cells and their microenvironment, stress responses to oxygen and nutrient gradients, translational impact of targeting the microenvironment, tumor immunity and immunotherapy.”
http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=73&DetailItemID=419
1-9-16 10:30am-12:45pm: Plenary Session 5: “Actions of Innate & Adaptive Immunity”
Chairperson: Joan Massague**, Memorial Sloan Kettering Inst.
1. Tak Mak, Univ./Toronto, “Beyond checkpoint blockade: Emerging strategies”
2. Elizabeth Jaffee, Johns Hopkins, “Tipping the balance from a procarcinogenic to...”
3. Jeffrey Molldrem, MD Anderson, “T cell receptor-like antibody 8F4 targets leukemia...”
4. Joan Massague, MSK-CC, “Latency & immune evasion of metastatic stem cells”
5. Rolf A. Brekken (PPHM SAB), UTSW-MC/Dallas, “Antibody mediated blockade of phosphatidylserine synergizes with immune checkpoint blockade by inhibiting multiple immune suppressive mechanisms”
- - - - - - -
**Dr. Joan Massague is not just some doc from MSK, he is the DIRECTOR OF THE SLOAN KETTERING INSTITUTE and a very well-known scientist.
http://www.mskcc.org/research-areas/programs-centers/ski/director-joan-massague
Here is a video of Dr. Massague talking about the “Next Wave” of cancer research: https://www.mskcc.org/research-areas/programs-centers/ski

= = = = = = = = = =
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/qxu4w2x

7-14-15 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/nw2v5u6
...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”

9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”

= = = = = = = = =
BAVI MOA 5-28-14: Dr. Rolf Brekken’s 47min CRI “Cancer Immunotherapy” webinar about Bavituximab as an Upstream/Global Immune Checkpoint Inhibitor – REPLAY: http://tinyurl.com/lxgftyx
. . .CRI=Cancer Research Institute (NYC – Supported by BMS): http://www.cancerresearch.org - Facebook: http://tinyurl.com/pbmhb2z , https://twitter.com/CancerResearch
. . .CRI launches “Answer to Cancer” (cancer immunotherapy) website http://www.theanswertocancer.org
. . .8-12-14: CRI adds Youtube links to the 5-28-14 CRI Immunotherapy webinar, incl. Dr. Brekken's talk "about Bavi and how it works against lung, liver, and other kinds of cancers" http://tinyurl.com/ps5h6h8
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)